Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg once weekly for weight management in adolescents with overweight or obesity
2018-002431-18Phase 3Unknown
- Sponsor
- Novo Nordisk
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Semaglutide arm with Placebo arm (2 arms). Primary endpoint: Change in BMI from baseline. Status: unknown.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2018-002431-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002431-18.